Isavuconazole – Basilea reports positive results from study

New Drug Approvals

Isavuconazole structure.svg
241479-67-4 CAS
946075-13-4 cas of SULPHATE (USAN)  in phase 3Aspergillosis, Infection, candidal, RO-0098557
ROCHE Originator
 ChemSpider 2D Image | Isavuconazole | C22H17F2N5OS
30 September 2013 – Basilea Pharmaceutica has revealed positive topline data from the isavuconazole phase 3 invasive aspergillosis study (SECURE). antifungal agent isavuconazole is being co-developed with Astellas Pharma Inc.The randomized, double-blind isavuconazole study (SECURE) achieved its primary objective in demonstrating non-inferiority versus voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus species or certain other filamentous fungi.

This post is updated in sept 2015……..


BAL-4815, 241479-67-4, Bal4815, AC1OCFHQ, UNII-60UTO373KE, , BAL 4815, FT-0670421
Molecular Formula: C22H17F2N5OS   Molecular Weight: 437.465086

Isavuconazole (BAL4815; trade name Cresemba) is a triazole antifungal drug. Its prodrug, isavuconazonium sulfate (BAL8557), was granted approval by the U.S. Food and Drug Administration (FDA) on March 6, 2015

View original post 3,732 more words

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s